Results 71 to 80 of about 136,281 (235)

Oral PHGG ameliorates atopic dermatitis‐like dermatitis with concurrent modulation of colonic IgA and cecal microbiota: implications for the gut–skin axis

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract BACKGROUND Atopic dermatitis (AD) is increasingly recognized as a systemic inflammatory disorder linked to intestinal immune and microbiome dysregulation. However, whether dietary galactomannan fibers can mitigate AD through coordinated modulation of the gut–skin axis remains unexplored.
Derrick Kakooza   +6 more
wiley   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg   +2 more
wiley   +1 more source

Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome. [PDF]

open access: yes, 2020
Netherton syndrome (NS) is a monogenic skin disease resulting from loss of function of lymphoepithelial Kazal-type-related protease inhibitor (LEKTI-1).
Butcher, Anna M   +12 more
core  

Prevalence and Burden of Somatic Symptom Disorder in Atopic Dermatitis and Chronic Pruritus—The Persistent Somatic Symptoms Across Diseases: Pruritus (SOMA.PRU) Study

open access: yesJEADV Clinical Practice, EarlyView.
In adults with atopic dermatitis and chronic pruritus, the mental comorbidity of Somatic Symptom Disorder is associated with higher average and worst pruritus intensity, higher psychological distress and lower quality of life. Additionally, there were nonsignificant changes in cutaneous nerve fiber densities in skin biopsies.
Stefan M. Kahnert   +13 more
wiley   +1 more source

Comparing Self‐Reported and Physician‐Assessed Acne Severity Using Real‐World Data

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Real‐world data (RWD) offers access to vast amounts of health information; however, limited knowledge exists regarding its reliability in clinical and research practices. Objectives To analyse the agreement between self‐assessed severity of self‐reported acne vulgaris (AV), and physician‐assessed severity based on photographic ...
Ali Al‐Mousawi   +7 more
wiley   +1 more source

Patient‐Reported Outcomes Selected by Paediatric Patients With Atopic Dermatitis in the Aiming High in Eczema/Atopic Dermatitis Approach

open access: yesJEADV Clinical Practice, EarlyView.
We surveyed 290 paediatric patients with atopic dermatitis (AD)/their caregivers to determine troublesome AD features described as PROs. The most selected were itch (0‐ to 5‐year‐old children: 85%; children aged ≥ 6 years: 89.3%), skin appearance/condition (69.9% and 61.6%, respectively), and sleep disturbance (38.1% and 25.4%, respectively ...
Yuji Fujita   +10 more
wiley   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson   +4 more
wiley   +1 more source

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won   +11 more
wiley   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni   +6 more
wiley   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

open access: yesJEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy